Dostarlimab and LB-100 for clear cell ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs—dostarlimab (an immunotherapy) and LB-100 (a new drug targeting a protein called PP2A)—for people with clear cell ovarian cancer that has returned or is resistant to platinum chemotherapy. The goal is to see if this combination is safe and effective for this specific type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have clear cell ovarian, peritoneal, or fallopian tube cancer that has come back or is not responding to platinum-based chemotherapy.
- You have had at least one prior treatment for your cancer, or your cancer became resistant to platinum within 6 months of your last platinum treatment.
- Your tumor does not have a PPP2R1A gene mutation (a specific genetic change).
- You have not been treated before with immunotherapy drugs like Keytruda, Opdivo, or Yervoy.
- You are between 18 and 75 years old, with good overall health and organ function (kidney, liver, blood counts).
- You do not have an active autoimmune disease or uncontrolled infections like hepatitis B, C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—liposomal irinotecan (chemotherapy), sintilimab (immunotherapy), and anlotinib (targeted therapy)—for people with recurrent or persistent ovarian clear cell carcinoma who have already tried platinum-based chemotherapy. The goal is to see if this triple therapy can shrink tumors or slow cancer growth.
This trial tests a combination of an immunotherapy drug (QL1706) and a targeted therapy (bevacizumab) for women with newly diagnosed advanced ovarian clear cell carcinoma. The goal is to see if this combination works better than standard treatment after surgery.
This trial tests a drug called dostarlimab alone or with bevacizumab compared to standard chemotherapy for women whose clear cell cancer of the ovary, uterus, cervix, vagina, or vulva has come back within a year of platinum chemotherapy. The goal is to see if these newer treatments can help control the cancer better.
This trial tests a combination of three drugs (RC48, AK104, and bevacizumab) for ovarian clear cell carcinoma, a type of ovarian cancer. The goal is to see if this combination can help shrink or control the cancer in people who have not had many prior treatments.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
This trial tests a new combination of drugs for ovarian cancer that has come back quickly after platinum-based chemo. The goal is to see if adding an immunotherapy and a targeted pill to non-platinum chemo can help shrink tumors.
Hear when a new Ovarian Clear Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.